Novo Nordisk's AI Bet and High-Dose Launch Face a Revenue Reality Check

Novo Nordisk shares staged a nearly 7.5 percent rally last week, a surprising move for a stock trading roughly 50 percent below its yearly high and considered technically oversold. This contradictory performance highlights the battle between strategic optimism and immediate financial headwinds facing the Danish pharmaceutical giant.

A key driver of the recent uptick was a newly announced partnership with OpenAI. The company plans to deploy artificial intelligence tools to analyze complex datasets, aiming to accelerate the timeline from research to drug approval. Pilot programs across research, production, and sales are launching immediately, with a company-wide integration targeted by the end of 2026. The stock gained approximately three percent on the day of the announcement.

This strategic push coincides with significant operational shifts. After cutting nearly 7,800 positions last year, Novo Nordisk has reversed course and hired about 2,000 new employees in 2025 to date. The recruitment focuses squarely on bolstering production, research, and commercial operations for its core diabetes and obesity therapies. Management is also aggressively executing a share buyback program. Since February, the company has repurchased nearly 11 million B-shares at an average price of around 257 Danish Kroner (DKK), for a total of roughly 2.8 billion DKK. The full program is authorized to spend up to 15 billion DKK by February 2026.

On the product front, a higher-dose version of its weight-loss drug, Wegovy HD (Semaglutid 7.2 mg), is now available in over 70,000 US pharmacies. Clinical data shows a stronger efficacy, with patients in the STEP-UP study losing an average of 20.7 percent of their body weight over 72 weeks, compared to 17.5 percent on the standard 2.4 mg dose. The pricing strategy is tiered: while cash-paying patients face a $399 monthly cost, those with private insurance may pay as little as $25.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

Despite these developments, Wall Street remains cautious. BMO Capital lowered its price target for Novo Nordisk from $45 to $36 on April 14, maintaining a "Market Perform" rating. Analysts there project disappointing quarterly revenue from the oral version of Wegovy, expecting first-quarter sales of around $136 million, which would fall short of market expectations. Jefferies also maintains a neutral stance on the stock.

The skepticism is rooted in several challenges. Currently, sales are skewed toward lower-dosed, cheaper Wegovy pills, which pressures overall revenue. Fierce competition is intensifying, notably from Eli Lilly's newly launched rival pill, Foundayo, which offers patients the advantage of not requiring a fasting period for administration. For 2026, Novo Nordisk's own management forecasts a currency-adjusted sales decline of five to 13 percent, citing pricing pressure and political headwinds in the US market.

The stock's technical picture reflects these concerns. Shares closed the week at 34.44 euros, marking a year-to-date decline of almost 23 percent. The price sits more than 20 percent below its 200-day moving average, and with a Relative Strength Index (RSI) reading of 25, the equity is technically deep in oversold territory.

Novo Nordisk at a turning point? This analysis reveals what investors need to know now.

All eyes are now on the first-quarter results due in May, which will reveal if higher prescription volumes can offset falling prices. A significant test for the stock's recent recovery will come in mid-2026, when Medicare is slated to decide on cost coverage for obesity medications. Until then, the market is weighing Novo Nordisk's long-term strategic bets against the stark reality of near-term revenue pressures and brutal competition.

Ad

Novo Nordisk Stock: New Analysis - 18 April

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

en | DK0062498333 | NOVO | boerse | 69197367 |